Rapamycin increases catalase and superoxide dismutase and reduces NLRP3 gene expression, thereby suppressing pentylenetetrazole-induced anxiety and depression-like manifestations (Aghaie et al., 2021). The gene discussed is NLRP3; the disease is depressive disorder.